Melanoma Metastatic Clinical Trials

9 recruiting

Melanoma Metastatic Trials at a Glance

9 actively recruiting trials for melanoma metastatic are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Phase 1 with 3 trials, with the heaviest enrollment activity in Melbourne, Bari, and Besançon. Lead sponsors running melanoma metastatic studies include Azienda Ospedaliera di Perugia, Centre Hospitalier Universitaire Vaudois, and Alpha-9 Oncology USA Inc..

Browse melanoma metastatic trials by phase

Treatments under study

About Melanoma Metastatic Clinical Trials

Looking for clinical trials for Melanoma Metastatic? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Melanoma Metastatic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Melanoma Metastatic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 2

Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma

Melanoma Metastatic
Melanoma Institute Australia129 enrolled5 locationsNCT06767306
Recruiting
Phase 1

A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma

Melanoma MetastaticMucosal MelanomaUveal Melanoma, Metastatic
Alpha-9 Oncology USA Inc.50 enrolled4 locationsNCT07076550
Recruiting
Phase 2

A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.

Triple Negative Breast Cancer MetastaticMelanoma MetastaticColorectal Cancer Metastatic
Fudan University95 enrolled1 locationNCT06889610
Recruiting
Not Applicable

Study to Evaluate Impact® as Support to Anti PD1 or Anti PD1 Based Regimen Treatment in Patients With Inoperable Locally Advanced or Metastatic Melanoma

Locally Advanced MelanomaMelanoma Metastatic
Fondazione Melanoma Onlus20 enrolled1 locationNCT06880198
Recruiting
Not Applicable

Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma Study

Melanoma Metastatic
Azienda Ospedaliera di Perugia35 enrolled5 locationsNCT07050940
Recruiting
Phase 1

NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma

SarcomaAdvanced MelanomaMelanoma Metastatic
Centre Hospitalier Universitaire Vaudois9 enrolled2 locationsNCT06889766
Recruiting

Observational Study of Patients With Advanced Melanoma (Skin Cancer) to Assess if IOpener®-Melanoma Test Can Predict Response to Immunotherapy.

Melanoma Metastatic
Pamgene International B.V.196 enrolled3 locationsNCT06784778
Recruiting
Phase 1

T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma

Melanoma Metastatic
Inge Marie Svane10 enrolled1 locationNCT06783270
Recruiting

Neoadjuvant Immunotherapy of Operable Metastatic Melanoma in Real Life (GCC)

Melanoma Metastatic
Centre Hospitalier Universitaire de Besancon77 enrolled9 locationsNCT06586593